Overview of Cervical Cancer Burden and Elimination Targets in India
Cervical cancer ranks as the second most common cancer among Indian women, accounting for 7.7% of all female cancers (National Cancer Registry Programme, ICMR 2022). Annually, India reports approximately 123,907 new cases and 77,348 deaths due to cervical cancer (GLOBOCAN 2020). The World Health Organization (WHO) has set a global elimination target by 2030, defined as reducing incidence below 4 per 100,000 women, requiring 90% HPV vaccination coverage, 70% screening coverage, and 90% treatment coverage.
India initiated a pilot HPV vaccination program in 2016 in select states, but national scale-up remains limited. Current HPV vaccination coverage among adolescent girls is under 10%, and cervical cancer screening coverage for women aged 30-49 is only 22% (NFHS-5, 2019-21). These figures highlight the gap between policy goals and ground realities.
UPSC Relevance
- GS Paper 2: Health policies, National Health Policy 2017, NPCDCS, Ayushman Bharat
- GS Paper 3: Public health infrastructure, non-communicable diseases
- Essay: Role of vaccination and screening in disease elimination
Legal and Policy Framework Governing Cervical Cancer Control
The Epidemic Diseases Act, 1897 provides a legal basis for public health emergencies but is less directly involved in cancer control. The Drugs and Cosmetics Act, 1940 regulates HPV vaccines, ensuring quality and safety standards. The National Health Policy 2017 explicitly addresses non-communicable diseases (NCDs) including cancer, emphasizing prevention through vaccination and screening.
Section 3 of the Pre-Conception and Pre-Natal Diagnostic Techniques (PCPNDT) Act, 1994 indirectly supports gender-sensitive health interventions by curbing sex-selective practices that impact women’s health. The Ayushman Bharat – Pradhan Mantri Jan Arogya Yojana (PM-JAY), launched in 2018, offers financial protection for cancer treatment, reducing out-of-pocket expenditure.
Economic Dimensions of Cervical Cancer Prevention and Treatment
The 2023-24 Union Budget allocated approximately ₹2,500 crore for cancer control, including HPV vaccination and screening programs. The HPV vaccine market in India is projected to grow at a CAGR of 15% from 2023 to 2028 (India Brand Equity Foundation, IBEF 2023). Government schemes estimate the cost of full HPV vaccination per girl at ₹1,000-1,500, making it a cost-effective preventive measure.
Treatment costs for cervical cancer average ₹1.5 lakh per patient in tertiary care settings (National Cancer Registry Programme, ICMR 2022). Productivity loss due to cervical cancer morbidity and mortality is estimated at ₹3,000 crore annually (Lancet Oncology, 2023). The National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS) operates with an annual budget of ₹500 crore for screening and awareness activities.
Institutional Roles in Cervical Cancer Control
- Indian Council of Medical Research (ICMR): Conducts epidemiological research and HPV vaccine trials.
- NPCDCS: Implements cervical cancer screening and awareness programs at the primary healthcare level.
- National AIDS Control Organisation (NACO): Integrates cervical cancer screening for HIV-positive women, who are at higher risk.
- World Health Organization (WHO): Provides technical guidelines and global elimination targets.
- Ministry of Health and Family Welfare (MoHFW): Oversees policy formulation, vaccination rollout, and program coordination.
- Non-Communicable Disease Cell (NCD Cell): Coordinates cancer control efforts under MoHFW.
Barriers to Effective HPV Vaccination and Screening in India
Fragmented HPV vaccine rollout and low screening uptake are driven by multiple factors: inadequate awareness, cultural stigma around sexual health, and weak primary healthcare infrastructure. Despite pilot programs, nationwide HPV vaccination lacks uniform implementation, with disparities across states and socio-economic groups.
Screening coverage remains low due to limited access to facilities, insufficient trained personnel, and poor follow-up mechanisms. Policy focus often prioritizes treatment over prevention, limiting resource allocation for vaccination and early detection.
Comparative Insights: Australia vs India
| Parameter | India | Australia |
|---|---|---|
| HPV Vaccination Coverage | <10% nationally (NFHS-5, 2019-21) | Over 80% via school-based programs (Australian Institute of Health and Welfare, 2023) |
| Screening Coverage (Women 30-49) | 22% (NFHS-5, 2019-21) | 70% with organized screening programs |
| Vaccination Program Model | Pilot state-wise rollout; limited national scale | National school-based subsidized vaccination |
| Projected Elimination Year | Not on track for 2030 target | Projected elimination by 2035 |
Way Forward: Strategies to Accelerate Cervical Cancer Elimination
- Scale up HPV vaccination through nationwide school-based programs with government subsidies to increase coverage towards WHO’s 90% target.
- Strengthen NPCDCS screening initiatives by expanding infrastructure, training healthcare workers, and integrating community awareness campaigns to improve uptake beyond 70%.
- Address socio-cultural barriers via targeted IEC (Information, Education, Communication) campaigns to reduce stigma and misinformation around HPV and cervical cancer.
- Leverage Ayushman Bharat PM-JAY to provide comprehensive financial protection covering both preventive and curative services.
- Enhance data collection and monitoring systems under ICMR and MoHFW to track vaccination, screening, and treatment outcomes for evidence-based policy adjustments.
Consider the following statements about HPV vaccination in India:
- HPV vaccination coverage among adolescent girls is above 50% nationally.
- The Drugs and Cosmetics Act, 1940 regulates the quality and safety of HPV vaccines in India.
- The National Health Policy 2017 includes cancer prevention as a priority area.
Which of the above statements is/are correct?
Answer: (b)
Statement 1 is incorrect because HPV vaccination coverage is below 10% nationally (NFHS-5, 2019-21). Statements 2 and 3 are correct as the Drugs and Cosmetics Act, 1940 regulates vaccines, and National Health Policy 2017 prioritizes cancer prevention.
Consider the following about cervical cancer screening in India:
- Screening coverage among women aged 30-49 is approximately 22% as per NFHS-5.
- The NPCDCS program has an annual budget exceeding ₹2,000 crore dedicated to cancer screening.
- The Ayushman Bharat PM-JAY scheme provides financial protection for cervical cancer treatment.
Which of the above statements is/are correct?
Answer: (c)
Statement 1 is correct as NFHS-5 reports 22% screening coverage. Statement 2 is incorrect; NPCDCS has an annual budget of ₹500 crore for screening (not over ₹2,000 crore). Statement 3 is correct as PM-JAY covers cancer treatment expenses.
Mains Question
Discuss the challenges and policy measures necessary for eliminating cervical cancer in India by 2030. (250 words)
Jharkhand & JPSC Relevance
- JPSC Paper: Paper 2 – Health and Social Issues; Paper 3 – Public Health Infrastructure
- Jharkhand Angle: Low HPV vaccination and screening coverage in tribal and rural populations; limited healthcare access increases cervical cancer burden.
- Mains Pointer: Emphasize state-level implementation gaps, socio-cultural barriers, and integration of NPCDCS with local health missions for Jharkhand.
What is the current HPV vaccination coverage among adolescent girls in India?
HPV vaccination coverage among adolescent girls in India is below 10% nationally as per NFHS-5 (2019-21), indicating limited reach beyond pilot programs.
Which Act regulates HPV vaccines in India?
The Drugs and Cosmetics Act, 1940 regulates the quality, safety, and approval of HPV vaccines in India.
What are the WHO targets for cervical cancer elimination by 2030?
WHO targets 90% HPV vaccination coverage of girls by age 15, 70% screening coverage of women aged 30-49, and 90% treatment coverage of detected cases by 2030.
How does Ayushman Bharat PM-JAY support cervical cancer patients?
PM-JAY provides financial protection by covering costs of cervical cancer treatment, reducing out-of-pocket expenses for eligible beneficiaries.
What are the main barriers to cervical cancer screening in India?
Barriers include lack of awareness, cultural stigma, inadequate primary healthcare infrastructure, and insufficient trained personnel for screening and follow-up.